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IMPORTANCE Although palmoplantar pustulosis (PPP) can significantly impact quality of life,
the factors underlying disease severity have not been studied.
OBJECTIVE To examine the factors associated with PPP severity.
DESIGN, SETTING, AND PARTICIPANTS An observational, cross-sectional study of 2 cohorts was
conducted. A UK data set including 203 patients was obtained through the Anakinra in
Pustular Psoriasis, Response in a Controlled Trial (2016-2019) and its sister research study
Pustular Psoriasis, Elucidating Underlying Mechanisms (2016-2020). A Northern European
cohort including 193 patients was independently ascertained by the European Rare and
Severe Psoriasis Expert Network (2014-2017). Patients had been recruited in secondary or
tertiary dermatology referral centers. All patients were of European descent. The PPP
diagnosis was established by dermatologists, based on clinical examination and/or published
consensus criteria. The present study was conducted from October 1, 2014, to March 15,
2020.
MAIN OUTCOMES AND MEASURES Demographic characteristics, comorbidities, smoking
status, Palmoplantar Pustulosis Psoriasis Area Severity Index (PPPASI), measuring severity
from 0 (no sign of disease) to 72 (very severe disease), or Physician Global Assessment (PGA),
measuring severity as 0 (clear), 1 (almost clear), 2 (mild), 3 (moderate), and 4 (severe).
RESULTS Among the 203 UK patients (43 men [21%], 160 women [79%]; median age at
onset, 48 [interquartile range (IQR), 38-59] years), the PPPASI was inversely correlated with
age of onset (r = −0.18, P = .01). Similarly, in the 159 Northern European patients who were
eligible for inclusion in this analysis (25 men [16%], 134 women [84%]; median age at onset,
45 [IQR, 34-53.3] years), the median age at onset was lower in individuals with a moderate to
severe PGA score (41 years [IQR, 30.5-52 years]) compared with those with a clear to mild
PGA score (46.5 years [IQR, 35-55 years]) (P = .04). In the UK sample, the median PPPASI
score was higher in women (9.6 [IQR, 3.0-16.2]) vs men (4.0 [IQR, 1.0-11.7]) (P = .01).
Likewise, moderate to severe PPP was more prevalent among Northern European women (57
of 134 [43%]) compared with men (5 of 25 [20%]) (P = .03). In the UK cohort, the median
PPPASI score was increased in current smokers (10.7 [IQR, 4.2-17.5]) compared with former
smokers (7 [IQR, 2.0-14.4]) and nonsmokers (2.2 [IQR, 1-6]) (P = .003). Comparable
differences were observed in the Northern European data set, as the prevalence of moderate
to severe PPP was higher in former and current smokers (51 of 130 [39%]) compared with
nonsmokers (6 of 24 [25%]) (P = .14).
CONCLUSIONS AND RELEVANCE The findings of this study suggest that PPP severity is
associated with early-onset disease, female sex, and smoking status. Thus, smoking cessation
intervention might be beneficial.
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P almoplantar pustulosis (PPP) is an uncommon pustu-lar eruption affecting the palms and/or soles. It is ob-served in approximately 1:2000 individuals of Euro-
pean descent and 1:800 individuals of East Asian descent.1 The
disease typically manifests in adulthood, with a median age
of onset older than 45 years reported in most studies.2 Palmo-
plantar pustulosis shows a marked sex bias, with women ac-
counting for 60% to 90% of affected individuals.2,3 The dis-
ease is also characterized by an association with cigarette
smoking, with up to 90% of patients self-identifying as smok-
ers at the time of diagnosis.2,4-6
The disease manifests with the eruption of sterile, neu-
trophil-filled pustules on the palms and soles. The lesions,
which can occur on a background of normal or inflamed skin,
are persistent (>3 months), painful, and disabling, and can be
accompanied by fissures, pruritus, and a burning sensation.7
Comorbidities are also common, as affected individuals are at
increased risk of psoriasis vulgaris, psoriatic arthritis, and au-
toimmune thyroid disease.8
While PPP can profoundly impact quality of life, the fac-
tors underlying variable disease severity have not been inves-
tigated. The rarity of the condition has hindered the ascertain-
ment and characterization of adequately powered data sets.
In this context, the objective of our study was 2-fold: to evalu-
ate the features of PPP in 2 independent patient cohorts and
to examine whether PPP severity is influenced by sex and
smoking status—the 2 most well-established risk factors for the
disease.1 Given that symptoms typically manifest in adult-
hood, we also sought to examine whether the presentation of
PPP is more severe in early-onset cases.
Methods
Patients
This study was carried out in accordance with the principles
of the Declaration of Helsinki9 and with the approval of the par-
ticipating institutions’ ethics committees. The present study
was approved by London Bridge Research ethics committee
(London, UK) and Kantonale Ethikkommission (Zurich, Swit-
zerland). All patients granted their informed consent in writ-
ing; participants did not receive financial compensation. This
study followed the Strengthening the Reporting of Observa-
tional Studies in Epidemiology (STROBE) reporting guideline
for cross-sectional studies. The present study was conducted
from October 1, 2014, to March 15, 2020.
The UK resource included 203 unrelated and prospec-
tively ascertained patients. Forty-two patients were re-
cruited between 2016 and 2019 through Anakinra in Pustular
Psoriasis, Response in a Controlled Trial (APRICOT).10 The re-
maining 161 patients were enrolled between 2016 and 2020
through the sister research study Pustular Psoriasis, Elucidat-
ing Underlying Mechanisms (PLUM).11 A total of 23 dermatol-
ogy centers located across the UK were involved in the recruit-
ment.
The Northern Europe resource included 193 unrelated pa-
tients. Affected individuals were mostly enrolled between 2014
and 2017 through 3 centers affiliated with the European Rare
and Severe Psoriasis Expert Network (ERASPEN). These cen-
ters were in the dermatology departments of the Medical Uni-
versity of Vienna, Austria (n = 100), Tartu University, Estonia
(n = 57), and University Medical Centre Schleswig-Holstein,
Campus Kiel, Germany (n = 31). The remaining 5 patients were
recruited outside the main reference centers by clinicians who
provided individual cases to the ERASPEN Consortium.
Pustular psoriasis was always diagnosed by a dermatolo-
gist, based on clinical examination and/or the ERASPEN con-
sensus criteria.7 The observation of sterile, macroscopically vis-
ible pustules on palms or soles was the main inclusion criterion.
Conversely, the presence of pustules restricted to the edges of
psoriatic plaques represented an exclusion criterion. Individu-
als with concomitant generalized pustular psoriasis or con-
comitant acrodermatitis continua of Hallopeau were also ex-
cluded from the study, given that lesions affecting nails or
nonacral skin are deemed incompatible with a diagnosis of
PPP.12
Clinical information and key demographics were collated
using a standardized case report form, shared by all centers.
In the UK cohort, disease severity was measured using the Pal-
moplantar Pustulosis Area Severity Index (PPPASI)13 and the
Dermatology Life Quality Index (DLQI) (eFigure 1 in the Supple-
ment). The PPPASI measures severity of the disease with scores
from 0 (no sign of disease) to 72 (very severe disease). The DLQI
measures quality of life with scores ranging from 0 to 30, with
higher scores indicating greater impairment. In the Northern
European cohort, patients were assessed with the Physician
Global Assessment (PGA), which has been shown to correlate
with the PPPASI.14 The individuals who recorded clinical data
and measured disease severity (reporting dermatologists or
trained research nurses) were blinded to the study objec-
tives.
Statistical Analysis
Given that different scoring systems were used in the UK and
Northern European cohorts, the 2 data sets were analyzed sepa-
rately. The quantitative PPPASI and DLQI measures obtained
in the UK cohort were analyzed using the Mann-Whitney test
for binary variables, such as sex, or the Kruskal-Wallis test for
categorical variables, such as smoking status. The correlation
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Palmoplantar Pustulosis Psoriasis Area Severity Index score was
significantly higher in women compared with men and in current
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between PPPASI or DLQI findings and age at onset was as-
sessed using the Spearman rank correlation coefficient. To ac-
count for the confounding effects of therapeutic interven-
tion, statistical significance was confirmed by regression
analysis. The PPPASI and DLQI values were normalized (square
root transformation) and analyzed vs sex, age of onset, or smok-
ing status, using treatment as a covariate.
To maximize statistical power, the categorical PGA scores
recorded in the Northern European data set were dichoto-
mized into clear to mild (including PGA-0 [clear], PGA-1 [al-
most clear], and PGA-2 [mild]) and moderate to severe (in-
cluding PGA-3 [moderate] and PGA-4 [severe]). The 2 groups
were then compared using the Fisher exact test. Given that the
purpose of the PGA analysis was to replicate results showing
statistical significance in the UK cohort, P values were com-
puted based on a 1-tailed distribution. As the number of indi-
viduals receiving systemic treatment was relatively small
(n = 25 from the Medical University of Vienna and 9 from Tartu
University), the confounding effect of therapeutic interven-
tion was addressed by excluding these cases from down-
stream analyses.
Individuals for whom information on smoking status or
age at onset was missing (Table) were excluded from the rel-
evant analyses. All statistical tests were implemented in R, ver-
sion 3.6.1 (R Project for Statistical Computing). P values <.05
were considered statistically significant.
Results
Patient Cohorts
The features of the UK and Northern European cohorts are sum-
marized in the Table. Among the 203 UK patients (43 men
[21%]; 160 women [79%]; median age at onset, 48 [interquar-
tile range (IQR), 38-59] years). The Northern European cohort
comprised 193 patients (32 men [17%]; 161 women [83%]; me-
dian age at onset, 45 [IQR, 33-54] years). Of these, 159 pa-
tients were available for analysis (25 men [16%]; 134 women
[84%]; median age at onset, 45 [IQR, 34-53.3] years). All pa-
tients were of European descent. The percentage of women
(>75%), median age of onset (≥45 years), and prevalence of cur-
rent and former smokers (>80%) were comparable in the 2 data
sets. Prominent nail involvement was observed in both study
populations, with more than 30% of patients presenting with
at least 1 of the following: pustules involving the nail appara-
tus, subungual hyperkeratosis, permanent nail loss, and non-
pustular nail dystrophy.
Concurrent psoriasis vulgaris was observed in substan-
tial numbers of study participants (66/203 [33%] UK patients
and 22/193 [11%] Northern European cases), while psoriatic ar-
thritis was reported in fewer patients from both cohorts (20/
203 [10%] UK cases and 17/193 [9%] Northern European indi-
viduals).
Autoimmune thyroid disease was reported in several af-
fected individuals from both data sets (14 of 203 [7%] of UK
cases and 25 of 193 [13%] of Northern European patients). The
prevalence of obesity (60 of 150 [40%] in the UK data set and
51 of 193 [26%] in the Northern European sample) was com-
parable to that observed among the overall population of Brit-
ish (36%),15 German (25%),16 and Estonian (21%)16 adults. In
keeping with this observation, no correlation between the body







Women, No. (%) 160/203 (79) 161/193 (83)
Men, No. (%) 43/203 (21) 32/193 (17)
Age at onset, median (IQR), yb 48 (38-59) 45 (33-54)
Family history of psoriasis vulgaris,
No. (%)
65/203 (32) 33/193 (17)
Family history of pustular psoriasis,
No. (%)
9/203 (4)c 10/93 (11)d
Smoking status, No. (%)
Current 90/203 (44) 124/193 (64)
Former 88/203 (43) 36/193 (19)
Never 23/203 (11) 28/193 (15)
Unknown 2/203 (1) 5/193 (3)
Clinical presentation
Disease duration, median (IQR), yb 6 (2-14) 16 (10-20)d
Nail involvement, No. (%) 65/203 (32) 64/193 (33)
Concurrent psoriasis vulgaris, No. (%) 66/203 (33) 22/193 (11)
Concurrent psoriatic arthritis, No. (%) 20/203 (10) 17/193 (9)
Severity
PPPASI score, median (IQR)e 8.2 (2.2-15.6) NA
DLQI score, median (IQR)f,g 10 (3.3-16) NA
On systemic treatment, No. (%)h 78/203 (38) 34/193 (18)
PGA score, No. (%)i NA
Clear/mild (0-2) 120/193 (62)
Moderate/severe (3-4) 73/193 (38)
Comorbid disease, No. (%)
Asthma 25/203 (12) 5/93 (5)d
Depression 31/203 (15) 28/193 (15)
Diabetes 26/203 (13) 29/193 (15)
Hypertension 41/203 (20) 58/193 (30)
Autoimmune thyroid disease 14/203 (7) 25/193 (13)
Obesityj 60/150 (40)k 51/193 (26)
Abbreviations: DLQI, Dermatology Life Quality Index; IQR, interquartile range;
NA, not applicable; PGA, Physician Global Assessment; PPPASI, Palmoplantar
Pustular Psoriasis Area Severity Index.
a All study participants were of European descent.
b Data not available for 11 UK cases and 1 Northern European case.
c One patient had a family history of both psoriasis vulgaris and pustular
psoriasis.
d Information not available for the 100 patients recruited in Vienna, Austria.
e PPPASI measures severity with scores from 0 (no sign of disease) to 72 (very
severe disease).
f Data not available for 8 UK cases.
g DLQI measures quality of life with scores from 0 to 30; higher scores indicate
greater impairment.
h On systemic treatment at the time of recruitment or the preceding 4 weeks.
i PGA measures severity as 0 (clear), 1 (almost clear), 2 (mild), 3 (moderate),
and 4 (severe).
j Body mass index greater than 30 (calculated as weight in kilograms divided by
height in meters squared).
k Data not available for 53 UK cases.
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mass index of patients with PPP and their PPPASI was noted
(Spearman r = 0.03, P = .61).
While different scoring systems were used in the 2 co-
horts, both included a substantial proportion of individuals
with severe PPP, reflecting ascertainment in hospital set-
tings. Specifically, 84 of 203 UK patients (41%) had a PPPASI
score greater than 10 and 73 of 193 of their Northern Euro-
pean counterparts (38%) had a PGA score greater than or equal
to 3 (Table).
Disease Severity
Among UK patients, age at onset was inversely correlated with
the PPPASI score (r = −0.18, P = .01) (Figure 1A), although not
with DLQI score (r = −0.08, P = .21). The association with the
PPPASI score remained significant when the confounding ef-
fect of systemic treatment was taken into account by linear re-
gression (P = .04) (eTable in the Supplement). In keeping with
these findings, the analysis of the Northern European cohort
revealed that the median age at onset was lower in patients with
moderate to severe PGA (41 [IQR, 30.5-52] years) compared
with those with clear to mild PGA (46.5 [IQR, 35.0-55.0] years)
(P = .04) (Figure 1B). Thus, severe PPP appeared to be associ-
ated with early disease onset.
In the UK sample, the median PPPASI score was higher in
women (9.6 [IQR, 3.0-16.2]) compared with men (4.0 [IQR, 1.0-
11.7]) (P = .01) (Figure 2A). The same applied to the median
DLQI (women: 10.5 [IQR, 4.3-17] vs men: 4 [IQR, 1-9];
P = 8.2 × 10−5) (eFigure 2 in the Supplement). Both associa-
tions were confirmed when systemic treatment was included
in a linear regression model (P = .03 for PPPASI, P < .001 for
DLQI) (eTable in the Supplement). In agreement with these ob-
servations, analysis of the Northern European data set re-
vealed that moderate to severe PPP was more prevalent among
women (57 of 134 [43%]) compared with men (5 of 25 [20%])
(P = .03) (Figure 2B). Thus, PPP severity appeared to be asso-
ciated with the sex of the patients in both the UK and North-
ern European study populations.
Among the UK patients, the median PPPASI score was high-
est in current smokers (10.7 [IQR, 4.2-17.5]), intermediate in
former smokers (7 [IQR, 2.0-14.4]), and lowest among non-
smokers (2.2 [IQR, 1-6]) (P = .003) (Figure 3A). Comparable
findings were obtained when the median DLQI scores were ana-
lyzed (current smokers: 10 [IQR, 4.8-16.3] vs former smokers:
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A, In the UK cohort, the Palmoplantar Pustulosis Psoriasis Area Severity Index
(PPPASI) score was inversely correlated with age of onset (r = −0.18, P = .01).
Regression lines are plotted with their 95% CIs (gray areas). B, In the Northern
European sample, age of onset was significantly lower among patients with
moderate-to-severe disease. Data are presented as median (interquartile
range). P < .05 per Mann-Whitney test. PPPASI measures severity with scores
from 0 (no sign of disease) to 72 (very severe disease).






























A, In the UK cohort, Palmoplantar Pustulosis Psoriasis Area Severity Index
(PPPASI) scores were significantly higher in women than men. Data are
presented as median (interquartile range). P < .01 per Mann-Whitney test. B, In
the Northern European sample, the proportion of individuals with moderate to
severe disease was significantly elevated in women compared with men. P < .05
per Fisher exact test. Physician Global Assessment (PGA) measures severity as
0 (clear), 1 (almost clear), 2 (mild), 3 (moderate), and 4 (severe). PPPASI
measures severity with scores from 0 (no sign of disease) to 72 (very severe
disease). PPP indicates palmoplantar pustulosis.
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9 [IQR, 3-17] vs nonsmokers: 5 [IQR, 1-10.8]) (P = .04) (eFig-
ure 3 in the Supplement). Both associations could be repli-
cated when the effects of systemic treatment were incorpo-
rated into a linear model (P = .005 for PPPASI, P = .04 for DLQI)
(eTable in the Supplement). The percentage of current smok-
ers (men: 18/43 [42%] and women: 72/160 [45%]) and former
smokers (men: 19/43 [44%] and women: 69/160 [43%]) was
comparable in the 2 sexes. Moreover, multivariable regres-
sion modeling found no evidence that the effect of smoking
differed by sex (data available from the authors).
While the analysis of the smaller Northern European data
set did not yield statistically significant results, we observed
a similar trend toward increased disease severity in smokers.
Moderate to severe PPP was more frequent among current and
former smokers (51 of 130 [39%]) than nonsmokers (6 of 24
[25%]) (P = .14) (Figure 3B).
Discussion
To our knowledge, this is the first systematic study of the fac-
tors associated with PPP severity. This study builds on previ-
ous work from our network, which enabled the definition of
consensus diagnostic criteria for PPP7 and suggested that the
disease is genetically different from other forms of pustular
psoriasis.2
Our investigation noted key epidemiologic features of
PPP, such as the late age of onset and sex bias (male-female
ratios were >1:3.5 in both cohorts). Psoriasis vulgaris con-
currence, which is frequently reported in PPP, was also
observed in the 2 data sets. While the prevalence of psoria-
sis vulgaris in the 2 cohorts was consistent with published
estimates (14%-61%),17 the number of individuals with both
PPP and psoriasis vulgaris was too small for subgroup analy-
ses, and the use of different scoring systems prevented us
from merging the UK and Northern European data sets.
Conversely, the study of the entire resource highlighted
aspects of PPP that, to our knowledge, had not been system-
atically investigated before.
We observed nail involvement in approximately one-
third of affected individuals. Subungual pustulation was re-
ported in a similar fraction of cases in a small UK study,18 sug-
gesting that nail abnormalities are a consistent feature of PPP.
We also report substantial comorbidity with psoriatic ar-
thritis, which was present in both cohorts at a frequency greater
than 9%. This percentage exceeds the prevalence of the dis-
ease in the general population (0.1%-0.3%).19
Obesity was relatively uncommon, affecting only one-
third of all study participants. This level contrasts with find-
ings obtained in psoriasis vulgaris studies, where the associa-
tion with obesity is well established20 and up to 42% of
individuals with severe disease have a body mass index greater
than 30.21
Overall, these findings suggest that PPP is part of the pso-
riasis spectrum because the substantial comorbidity with pso-
riasis vulgaris and psoriatic arthritis points to shared patho-
genic pathways. At the same time, the distinctive demographics
of PPP suggest the involvement of risk factors that are spe-
cific to this disease. For example, the female bias that charac-
terizes PPP is not observed in palmoplantar psoriasis.22 Like-
wise, psoriasis vulgaris affects both sexes equally23 and
occurred with comparable frequency in the male (15/28 [35%])
and female (51/160 [32%]) patients examined in this study
(P = .72).
Our analysis of PPPASI and PGA scores suggests that
PPP severity is higher in women vs men. Further experi-
mental studies will be required to dissect the causes of this
phenomenon. These sources may involve genetic modifiers
or hormonal imbalances that could be targeted for disease
treatment.
Our study also noted an association between cigarette
smoking and disease severity that was statistically signifi-
cant in the UK cohort (P < .01), where PPPASI values were high-
est in smokers, intermediate in former smokers, and lowest in
nonsmokers. This observation suggests a clinically relevant
dosage effect that may be validated and refined by analyzing
pack-year data in further patient resources.
Smoking cessation is sometimes applied to the manage-
ment of PPP and was found to be beneficial in a pilot study.24,25
In this context, our findings suggest that smoking cessation
should be systematically investigated in adequately powered
trials.
Limitations
This study has limitations. The setting was exclusively
based in secondary and tertiary referral centers, where the
proportion of patients with severe PPP and the burden of
comorbid disease may be higher than in other settings.




































A, In the UK cohort, Palmoplantar Pustulosis Psoriasis Area Severity Index
(PPPASI) scores are highest in current smokers, intermediate in former smokers
and lowest in never smokers. Data are presented as median (interquartile
range). P < .01 per Kruskal-Wallis test. B, In the Northern European sample, the
proportion of individuals with moderate to severe disease was elevated in
current and former smokers compared with never smokers. Physician Global
Assessment (PGA) measures severity as 0 (clear), 1 (almost clear), 2 (mild), 3
(moderate), and 4 (severe). PPPASI measures severity with scores from 0 (no
sign of disease) to 72 (very severe disease). PPP indicates palmoplantar
pustulosis.
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Thus, the potential for ascertainment bias limits the gener-
alizability of our findings.
Different measures of disease severity were used in the UK
(DLQI and PPPASI) and Northern European cohorts (PGA). Al-
though these scales are widely used in clinical practice, our re-
sults suggest that the categorical nature of the PGA tool af-
fected the statistical power of the Northern European cohort
and limited our ability to apply correlation-based methods.
Thus, quantitative measurements, such as the PPPASI, or even
more-sensitive methods, such as machine-learning–based pus-
tule counts, should be considered the standard for studies of
PPP severity.
Conclusions
The findings from this cross-sectional study note the ben-
efits of multicenter collaboration and standardized data col-
lection in the analysis of rare skin diseases. The study also sug-
gests that PPP symptoms are particularly severe in patients with
early-onset disease, women, and current smokers. The asso-
ciation between the severity of the disease and smoking will
need to be replicated in further data sets; however, the in-
creased severity suggests that smoking cessation interven-
tions may benefit the treatment of PPP.
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